title: DFD-01: a novel topical formulation of betamethasone dipropionate for the treatment of extensive psoriasis.
abstract: Betamethasone dipropionate has been used for the topical treatment of psoriasis in multiple formulations. DFD-01 (Sernivo™, Promius Pharma LLC) is a new midpotent lotion formulation of betamethasone dipropionate 0.05% that has recently been approved for the treatment of mild to moderate psoriasis for up to 4 weeks. Areas covered: This review will critically appraise available clinical information on DFD-01. Phase 3 efficacy and safety results will be reviewed on head-to-head comparison of DFD-01 with a superpotent augmented betamethasone dipropionate 0.05% lotion. It is suggested that the formulation of DFD-01 has enabled this midpotent topical steroid to demonstrate equivalent efficacy to a superpotent steroid. Expert commentary: DFD-01's unique advantage is that this product has the efficacy of a higher potency steroid but with the safety profile of a mid-potency steroid based on VCA assays. This formulation also has aesthetic appeal, which may benefit compliance.
authors.affiliation: a Dermatology Institute and Skin Care Center , Santa Monica , CA , USA.|b Division of Dermatology , David Geffen School of Medicine at UCLA , Los Angeles , CA , USA.
authors.forename: Paul
authors.initials: P
authors.lastname: Yamauchi
mesh_terms: D000287:Administration, Topical; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D001623:Betamethasone / Q000031:analogs & derivatives* / Q000627:therapeutic use; D017326:Clinical Trials, Phase III as Topic; D006801:Humans; D010349:Patient Compliance; D011565:Psoriasis / Q000188:drug therapy*; D063465:Skin Cream; D016896:Treatment Outcome
chemical_list: D000893:Anti-Inflammatory Agents; C011175:betamethasone-17,21-dipropionate; D001623:Betamethasone
keywords: Betamethasone dipropionate; erythema; formulation; psoriasis; scaling